Tackling unmet needs in lymphoma
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al.
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?